Arthur Biller is an associate in the Denver office (*not yet licensed in Colorado) of Lewis Brisbois and is a member of the Complex Business & Commercial Litigation, Government Investigations, Securities Litigation & FINRA, and White Collar Criminal Defense Practices.
Arthur has experience representing private equity firms, hedge funds, and public and private companies in all stages of civil litigation in federal and state courts, at both the trial court and appellate levels, as well as before the SEC and U.S. Attorney’s Office.
Arthur has experience in matters involving breach of contract, breach of fiduciary duty, veil-piercing, fraudulent transfer, successor liability, employment discrimination, insider trading, the Securities Act of 1933, the Securities Exchange Act of 1934, disputes over securitized trusts, and professional negligence.
Prior to joining Lewis Brisbois, Arthur was an associate at a large law firm in New York. Arthur earned his Juris Doctor, cum laude from New York University School of Law and his Bachelor of Arts, magna cum laude from New York University. After graduating from law school, Arthur clerked on the Supreme Court of New Jersey for the Honorable Helen E. Hoens.
- New York University School of Law, Juris Doctor, cum laude, 2010
- New York University, Bachelor of Arts, magna cum laude, 2007
- State Bar Admissions, New Jersey
- United States District Courts,
- United States District Court for the District of New Jersey
- United States District Court for the Southern District of New York
Representative Matters :
- Represented large hedge fund and its founder in insider trading investigation in SDNY
- Represented private company in employment discrimination case against EEOC involving over 30 individual claimants
- Represented private equity firm and portfolio company against claims of successor liability and fraudulent transfer
- Pro bono representation of class of transgender Medicaid recipients against New York State Department of Health in class action litigation in SDNY
- Represented public company in securities class actions arising out of alleged misrepresentations and omissions relating to results of clinical drug trial
Rate : $$$$